PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
AID  - 10.1136/jitc-2023-006833corr1
DP  - 2024 Jan 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e006833corr1
VI  - 12
IP  - 1
4099  - http://jitc.bmj.com/content/12/1/e006833corr1.short
4100  - http://jitc.bmj.com/content/12/1/e006833corr1.full
SO  - J Immunother Cancer2024 Jan 01; 12